What's Macquarie's price target for NIB shares?

Is the broker positive or negative on NIB's shares?

| More on:
Private health insurance diagram.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The NIB Holdings Ltd (ASX: NHF) share price has slipped slightly this morning. As of 11 am, shares are trading 0.81% lower at $7.35 a piece.

NIB's share price has jumped 33.1% since January. But thanks to a steep 17.8% plunge in late-August last year, the health insurer's share price is still down 2.26% for the year.

In a recent note to investors, Macquarie Group Ltd (ASX: MQG) revealed what it expects for NIB's share price over the next 12 months.

Macquarie's stance on NIB shares

The broker has confirmed its underperform rating on NIB shares and its target price of $5.60. 

That represents a potential downside of 23.8% for investors over the next 12 months.

"With multiple divisions experiencing operational and environmental headwinds, we retain our cautious outlook," Macquarie said in its note.

Macquarie expects more political and regulatory risk in FY 2026 as the Health Minister takes a second term and government focus on NDIS funding intensifies.

What to keep an eye on

Key catalysts to watch are the government review into phoenixing – where a company is deliberately liquidated to avoid paying debts before being restarted under another name, changes to the price approval process, changes to the student deed, and findings of the PALM (Pacific Australia Labour Mobility scheme) review.

Macquarie notes:

Residents – Payout Ratio: We expect further direction from the Department of Health on #1) phoenixing; #2) look-back mechanism for price approval, and #3) limits to "free periods", to be released over CY25 and impact CY26 results: "Why a claims payout ratio misses the mark" published 13 Jun '25. Worst case: this accounts for ~12.4% of Group UOP by FY27.

It adds that for international workers, even if NIB retains the PALM contract, it is unlikely to retain the high margins it enjoyed previously. At worst, this could account for 2.5% of the group's underlying operating profit or 4%-5% of the group's underlying operating profit with 50% stranded costs. It also said:

International – Students: NHF's costs are below the 12% commission cap so we foresee this change having limited impact. […] Worst case: this accounts for ~2.2% of Group UOP, before stranded costs and potential knock-on for residents.

For NDIS funding, the broker expects earnings declines in the coming 18-24 months as scheme reform remains elusive. In a worst-case scenario, this could account for 4.8% of the group's underlying operating profit. 

Macquarie notes that a new division head has been appointed to NIB New Zealand. This could pose a downside earnings risk as high as 6.6% on the group's underlying operating profit.

Earnings changes: FY25E: +1.8%; FY26E: -3.6%; and -1% to -5% for FY27 to FY29 reflecting above mentioned divisional challenges and MTMs.

Motley Fool contributor Samantha Menzies has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Macquarie Group. The Motley Fool Australia has positions in and has recommended Macquarie Group and NIB Holdings. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Wife and husband with a laptop on a sofa over the moon at good news.
Healthcare Shares

Heres what $1k invested in Mesoblast shares a month ago is worth now

This stock has exploded in the last month.

Read more »

A doctor looks unsure.
Healthcare Shares

Should you buy the rebound in CSL shares today?

Two leading experts deliver their verdicts for CSL shares.

Read more »

Medical workers examine an xray or scan in a hospital laboratory.
Healthcare Shares

Up 129% in a year, are Pro Medicus shares a buy ahead of tomorrow's FY 2025 results?

A leading expert delivers his verdict on the surging Pro Medicus share price.

Read more »

Medical workers examine an xray or scan in a hospital laboratory.
Healthcare Shares

Poor prognosis: Expert says sell these 2 ASX 200 healthcare giants now

Jed Richards from Shaw and Partners has a sell rating on both healthcare shares.

Read more »

Man pointing an upward line on a bar graph symbolising a rising share price.
Healthcare Shares

Why this ASX 200 stock could jump 25%

Bell Potter has good things to say about this stock.

Read more »

Shot of a young scientist looking stressed out while working on a computer in a lab.
Healthcare Shares

Guess which ASX All Ords stock just crashed 23% on earnings miss

Investors are sending the ASX All Ords stock tumbling on Friday. But why?

Read more »

Lab worker puts hands in the air and dances around.
Healthcare Shares

Guess which ASX 300 stock just jumped 12% on FDA approval

Investors are piling into the ASX 300 stock following big US news.

Read more »

A bearded man holds both arms up diagonally and points with his index fingers to the sky with a thrilled look on his face over these rising Tassal share price
Healthcare Shares

Broker says Telix shares could surge 80% higher after selloff

Let's see what Bell Potter has to say about this beaten down healthcare share.

Read more »